567 related articles for article (PubMed ID: 30604305)
1. Agranulocytosis-Protective Olanzapine-Loaded Nanostructured Lipid Carriers Engineered for CNS Delivery: Optimization and Hematological Toxicity Studies.
Gadhave DG; Tagalpallewar AA; Kokare CR
AAPS PharmSciTech; 2019 Jan; 20(1):22. PubMed ID: 30604305
[TBL] [Abstract][Full Text] [Related]
2. Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: optimization and in vivo studies.
Gadhave DG; Kokare CR
Drug Dev Ind Pharm; 2019 May; 45(5):839-851. PubMed ID: 30702966
[TBL] [Abstract][Full Text] [Related]
3. Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer's disease using Box-Behnken design.
Jojo GM; Kuppusamy G; De A; Karri VVSNR
Drug Dev Ind Pharm; 2019 Jul; 45(7):1061-1072. PubMed ID: 30922126
[TBL] [Abstract][Full Text] [Related]
4. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments.
Soni K; Rizwanullah M; Kohli K
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):15-31. PubMed ID: 29183147
[TBL] [Abstract][Full Text] [Related]
5. Passive and active strategies for transdermal delivery using co-encapsulating nanostructured lipid carriers: in vitro vs. in vivo studies.
Vitorino C; Almeida A; Sousa J; Lamarche I; Gobin P; Marchand S; Couet W; Olivier JC; Pais A
Eur J Pharm Biopharm; 2014 Feb; 86(2):133-44. PubMed ID: 24333401
[TBL] [Abstract][Full Text] [Related]
6. Optimization of artemether-loaded NLC for intranasal delivery using central composite design.
Jain K; Sood S; Gowthamarajan K
Drug Deliv; 2015; 22(7):940-54. PubMed ID: 24512368
[TBL] [Abstract][Full Text] [Related]
7. Intranasal Surface-Modified Mosapride Citrate-Loaded Nanostructured Lipid Carriers (MOS-SMNLCs) for Treatment of Reflux Diseases: In vitro Optimization, Pharmacodynamics, and Pharmacokinetic Studies.
Hammad RW; Sanad RAB; Abdelmalk NS; Aziz RL; Torad FA
AAPS PharmSciTech; 2018 Nov; 19(8):3791-3808. PubMed ID: 30280358
[TBL] [Abstract][Full Text] [Related]
8. Size-exclusive effect of nanostructured lipid carriers on oral drug delivery.
Li H; Chen M; Su Z; Sun M; Ping Q
Int J Pharm; 2016 Sep; 511(1):524-537. PubMed ID: 27452421
[TBL] [Abstract][Full Text] [Related]
9. Nose-to-brain delivery of sumatriptan-loaded nanostructured lipid carriers: preparation, optimization, characterization and pharmacokinetic evaluation.
Masjedi M; Azadi A; Heidari R; Mohammadi-Samani S
J Pharm Pharmacol; 2020 Oct; 72(10):1341-1351. PubMed ID: 32579251
[TBL] [Abstract][Full Text] [Related]
10. Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies.
Selvaraj BR; Sridhar SK; Kesavan BR; Palagati S
Pharm Nanotechnol; 2020; 8(6):452-470. PubMed ID: 32988361
[TBL] [Abstract][Full Text] [Related]
11. Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson's Disease.
Mishra N; Sharma S; Deshmukh R; Kumar A; Sharma R
Cent Nerv Syst Agents Med Chem; 2019; 19(1):46-56. PubMed ID: 30474538
[TBL] [Abstract][Full Text] [Related]
12. Brain targeting of olanzapine via intranasal delivery of core-shell difunctional block copolymer mixed nanomicellar carriers: in vitro characterization, ex vivo estimation of nasal toxicity and in vivo biodistribution studies.
Abdelbary GA; Tadros MI
Int J Pharm; 2013 Aug; 452(1-2):300-10. PubMed ID: 23684658
[TBL] [Abstract][Full Text] [Related]
13. Optimization, stabilization, and characterization of amphotericin B loaded nanostructured lipid carriers for ocular drug delivery.
Lakhani P; Patil A; Wu KW; Sweeney C; Tripathi S; Avula B; Taskar P; Khan S; Majumdar S
Int J Pharm; 2019 Dec; 572():118771. PubMed ID: 31669555
[TBL] [Abstract][Full Text] [Related]
14. Nanostructured lipid carriers (NLC) based controlled release topical gel of clobetasol propionate: design and in vivo characterization.
Nagaich U; Gulati N
Drug Deliv Transl Res; 2016 Jun; 6(3):289-98. PubMed ID: 27072979
[TBL] [Abstract][Full Text] [Related]
15. Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers.
Rizwanullah M; Amin S; Ahmad J
J Drug Target; 2017 Jan; 25(1):58-74. PubMed ID: 27186665
[TBL] [Abstract][Full Text] [Related]
16. Surface engineered nanostructured lipid carriers for efficient nose to brain delivery of ondansetron HCl using Delonix regia gum as a natural mucoadhesive polymer.
Devkar TB; Tekade AR; Khandelwal KR
Colloids Surf B Biointerfaces; 2014 Oct; 122():143-150. PubMed ID: 25033434
[TBL] [Abstract][Full Text] [Related]
17. Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route.
Gabal YM; Kamel AO; Sammour OA; Elshafeey AH
Int J Pharm; 2014 Oct; 473(1-2):442-57. PubMed ID: 25062866
[TBL] [Abstract][Full Text] [Related]
18. Optimization of Nanostructured Lipid Carriers of Lurasidone Hydrochloride Using Box-Behnken Design for Brain Targeting: In Vitro and In Vivo Studies.
Jazuli I; Annu ; Nabi B; Moolakkadath T; Alam T; Baboota S; Ali J
J Pharm Sci; 2019 Sep; 108(9):3082-3090. PubMed ID: 31077685
[TBL] [Abstract][Full Text] [Related]
19. Nose to Brain Delivery of Rivastigmine by In Situ Gelling Cationic Nanostructured Lipid Carriers: Enhanced Brain Distribution and Pharmacodynamics.
Wavikar P; Pai R; Vavia P
J Pharm Sci; 2017 Dec; 106(12):3613-3622. PubMed ID: 28923321
[TBL] [Abstract][Full Text] [Related]
20. Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery.
Noor NM; Sheikh K; Somavarapu S; Taylor KMG
Eur J Pharm Biopharm; 2017 Aug; 117():372-384. PubMed ID: 28412472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
